trending Market Intelligence /marketintelligence/en/news-insights/trending/py3khab5-sob6laq5juxva2 content
Log in to other products

Login to Market Intelligence Platform

 /

Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Indivior secures license for C4X Discovery's therapies for substance addiction

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Indivior secures license for C4X Discovery's therapies for substance addiction

Indivior PLC agreed to buy exclusive global rights to develop and commercialize U.K.-based C4X Discovery Holdings PLC's potential treatment for substance addiction.

Under the agreement, the Richmond, Va.-based Indivior would pay C4X $10 million upfront, with potential milestone payments of up to $284 million.

The deal involves C4X Discovery's drugs, including lead candidate C4X3256, that block the orexin-1 protein in the body to decrease addiction related to opioids, alcohol and psychomotor stimulants such as cocaine.